Limit up. It is being bought on the basis of the material that the first case was registered on June 10, 2024 in the Phase IIa clinical trial of the injection Brincidofovir for cytomegalovirus infection after hematopoietic stem cell transplantation underway in the United States. The trial added cytomegalovirus infection as a new indication by changing the protocol as additional indications for the Phase IIa trial for adenovirus infection in immunodeficient states currently underway, which was accepted by the Food and Drug Administration (FDA) in February this year.
シンバイオ製薬---ストップ高、CMV感染症対象の注射剤を材料視
Shin'bio Pharmaceuticals - trading limit up. Injectable drug for CMV infection is being considered as a material.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.